Stay updated on Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    Added a background citation: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer (N Engl J Med 2012;366:2455-2465) to the study page. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-12-09T00:53:28.000Z thumbnail image
  2. Check
    14 days ago
    Change Detected
    Summary
    The page shows a revision update from v3.3.1 to v3.3.2, a footer-level change that does not alter study details or user actions. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-12-01T18:51:33.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    Added Revision: v3.3.1 and removed the citation 'Safety and activity of anti-PD-L1 antibody in patients with advanced cancer' (N Engl J Med. 2012) along with Revision: v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-11-24T15:04:53.000Z thumbnail image
  4. Check
    29 days ago
    Change Detected
    Summary
    Added a reference: Pembrolizumab for the treatment of non-small-cell lung cancer (N Engl J Med. 2015;372:2018-2028). Removed a government funding status notice and a 1994 NEJM trial citation (preoperative chemotherapy plus surgery vs surgery alone).
    Difference
    0.6%
    Check dated 2025-11-17T07:44:08.000Z thumbnail image
  5. Check
    43 days ago
    Change Detected
    Summary
    Added a reference to a historical randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in non-small-cell lung cancer (N Engl J Med 1994; 330:153-158).
    Difference
    0.5%
    Check dated 2025-11-03T01:28:49.000Z thumbnail image
  6. Check
    57 days ago
    Change Detected
    Summary
    Removed two cited references: a 2012 NEJM article on anti-PD-L1 therapy and a 1994 NEJM trial on preoperative chemotherapy plus surgery for NSCLC; this reduces the page’s bibliographic support and mentions of key sources.
    Difference
    1%
    Check dated 2025-10-19T16:37:47.000Z thumbnail image

Stay in the know with updates to Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page.